Navigation Links
U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
Date:6/18/2008

uma trial. In carrying out that agreement, the Navy designed and submitted to the FDA a proposed phase 2/3 trial entitled "Restore Effective Survival in Shock" (RESUS). That trial would have been conducted prehospital in civilian trauma patients. The trial was placed on clinical hold by the FDA and continues to be on hold following changes intended to address FDA comments. The newly filed protocol, by incorporating informed consent, is intended to remove requirements attendant to waiver of informed consent. To date, Congress has appropriated a total of $24.2 million for the development of Hemopure.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward- looking statements, including any statements implying that any clinical trial will be initiated and/or carried out to completion or that study results will be as desired, and any statements that might imply that Hemopure may receive marketing approval in any jurisdictions other than South Africa or for a trauma indication anywhere. Actual results and their timing may differ materially from those projected in these for
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... ... September 01, 2015 , ... ... established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It is ... alliance is dedicated to the provision of quality addiction treatment and the ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... send information about new patients directly from Practice Perfect to FOTO enabling cost ... entry. , Steven Presement, President of Practice Perfect, stated "FOTO ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder and ... first in the area to offer RADIESSE® filler treatment for volume loss in the ... of tendons and veins in the hands, delivering smooth, natural-looking results that can last ...
(Date:9/1/2015)... ... , ... Routines… every family has them. Whether it’s a morning routine, meal ... caregivers and children too. Here are three reasons why routines can be beneficial for ... When a routine is implemented into a child’s schedule, they are able to anticipate ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) practicing in ... of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic surgeon ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... Relief of menstrual pain, migraines and acne may ... , TUESDAY, Dec. 22 (HealthDay News) -- Along ... disorders such as severe menstrual pain and heavy ... issued by the American College of Obstetricians and ...
... ... consulting firm, won a coveted Brandon Hall silver award for excellence in the ... ... e-Learning Course: The award-winning “APEX-Optics Bronze Certification” custom e-learning course, developed for Essilor ...
... , SHENZHEN, ... http://www.htdsmedical.com ) would like to announce that it has ... to a large modern herbal medicine company in China. The ... premium herbs, herbal extracts and herbal preparations. Name of the ...
... 2009 When Craig Harrison found out he would be ... surgery, an operation performed at UT Southwestern Medical Center, he ... been, but I was actually excited about it," Mr. Harrison ... Dr. J. Michael DiMaio, associate professor of cardiovascular and ...
... classrooms may contain higher levels of extremely small particles ... than polluted outdoor air, scientists in Australia and ... journal Environmental Science & Technology . Lidia ... over the health effects of airborne ultrafine particles. Evidence ...
... ATLANTA, Dec. 22 Craneware, Inc. ... that improve healthcare providers, financial performance, announced today that Chargemaster ... - Chargemaster Management market category in the "2009 Top 20 ... December 2009. KLAS is the leading source of healthcare information ...
Cached Medicine News:Health News:The 'Pill' Offers Benefits Beyond Birth Control 2Health News:Allen Interactions Receives Silver Brandon Hall Learning Award 2Health News:Allen Interactions Receives Silver Brandon Hall Learning Award 3Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 2Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 3Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 4Health News:Fort Worth patient first in North Texas to undergo robot-assisted surgery for removal of lung tumor 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: